key: cord-0833379-hi765z8p
authors: Ashokkumar, Chethan; Rohan, Vinayak; Kroemer, Alexander H; Rao, Sohail; Mazariegos, George; Higgs, Brandon W; Nadig, Satish; Almeda, Jose; Dhani, Harmeet; Khan, Khalid; Yazigi, Nada; Ekong, Udeme; Kaufman, Stuart; Betancourt-Garcia, Monica M; Mukund, Kavitha; Sethi, Pradeep; Mehrotra, Shikhar; Soltys, Kyle; Singh, Manasi S; Bond, Geoffrey; Khanna, Ajai; Ningappa, Mylarappa; Spishock, Brianna; Sindhi, Elizabeth; Atale, Neha; Saunders, Maggie; Baliga, Prabhakar; Fishbein, Thomas; Subramaniam, Shankar; Sindhi, Rakesh
title: Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients
date: 2021-05-04
journal: bioRxiv
DOI: 10.1101/2021.05.03.442371
sha: f626d97935b55fc91d0e5583b97517b912e382dc
doc_id: 833379
cord_uid: hi765z8p

Assessment of T-cell immunity to the COVID-19 coronavirus requires reliable assays and is of great interest, given the uncertain longevity of the antibody response. Some recent reports have used immunodominant spike (S) antigenic peptides and anti-CD28 co-stimulation in varying combinations to assess T-cell immunity to SARS-CoV-2. These assays may cause T-cell hyperstimulation and could overestimate antiviral immunity in chronically immunosuppressed transplant recipients, who are predisposed to infections and vaccination failures. Here, we evaluate CD154-expressing T-cells induced by unselected S antigenic peptides in 204 subjects-103 COVID-19 patients and 101 healthy unexposed subjects. Subjects included 72 transplanted and 130 non-transplanted subjects. S-reactive CD154+T-cells co-express and can thus substitute for IFNγ (n=3). Assay reproducibility in a variety of conditions was acceptable with coefficient of variation of 2-10.6%. S-reactive CD154+T-cell frequencies were a) higher in 42 healthy unexposed transplant recipients who were sampled pre-pandemic, compared with 59 healthy non-transplanted subjects (p=0.02), b) lower in Tr COVID-19 patients compared with healthy transplant patients (p<0.0001), c) lower in Tr patients with severe COVID-19 (p<0.0001), or COVID-19 requiring hospitalization (p<0.05), compared with healthy Tr recipients. S-reactive T-cells were not significantly different between the various COVID-19 disease categories in NT recipients. Among transplant recipients with COVID-19, cytomegalovirus co-infection occurred in 34%; further, CMV-specific T-cells (p<0.001) and incidence of anti-receptor-binding-domain IgG (p=0.011) were lower compared with non-transplanted COVID-19 patients. Healthy unexposed transplant recipients exhibit pre-existing T-cell immunity to SARS-CoV-2. COVID-19 infection leads to impaired T-cell and antibody responses to SARS-CoV-2 and increased risk of CMV co-infection in transplant recipients.

In chronically immunosuppressed transplant recipients (Tr), the status of immunity to COVID-19 infection is of great interest. This population is prone to life-threatening consequences of viral infection and failure of vaccination during periods marked by use of highdose immunosuppression 1 . Lifelong use of anti-rejection immunosuppressants contributes to this impairment and may also limit post-infectious and post-vaccination immunity to SARS-CoV-2 2, 3 .

Although antibodies can be demonstrated after natural COVID-19 infection and vaccination in the general population, this information is not available for Tr recipients [4] [5] [6] [7] [8] [9] [10] [11] . Pre-existing T-cells that recognize SARS-CoV-2 are another component of immunity to this virus [12] [13] [14] [15] . This type of immunity arises from prior exposure to human coronaviruses (hCoV), which account for 15% of seasonal flu and have structural similarities to SARS-CoV-2 [16] [17] . Pre-existing cellular immunity may also compensate for impaired antibody responses to COVID-19 infection and vaccination, and aid in combating variant strains that are starting to emerge. T-cell immunity may also reassure those individuals wishing to re-engage with the general public, but who are unable to tolerate vaccination or fail to achieve a durable antibody response. Pre-existing cellular immunity to SARS-CoV-2 has been demonstrated in non-transplanted subjects, but not in Tr recipients [12] [13] [14] [15] .

Recently proposed assays which measure T-cell immunity to SARS-CoV-2 may need to be modified to characterize T-cell immunity in Tr recipients. Some assays stimulate T-cells with those peptides representing the spike protein S, which have high affinity to well represented HLA specificities in a given population 13, 14 . Such peptide mixtures can potentially overstimulate T-cells from individuals with these HLA specificities, but not T-cells from underrepresented individuals.

Other assays also use the co-stimulators, anti-CD28 alone, or with anti-CD49d 12, 14 . These adjunctive stimuli can also lead to an overestimate of T-cell immunity. Clinical decisions founded on such overestimates can be falsely reassuring in chronically immunosuppressed patients, and lead to errors in clinical judgement with adverse consequences. Some assays also use cytotoxic intracellular staining procedures, or only count those cells which co-express multiple markers as antigen-reactive. Such multi-marker assays require large numbers of cells from individuals with COVID-19 infection, who can be severely lymphopenic, and sophisticated laboratories. Another challenge is extrapolating findings from these studies, all of which have been performed in nontransplant (NT) subjects who were recently diagnosed or were convalescing, to Tr recipients.

Higher frequencies of S-reactive T-cells were observed in convalescent and non-critically ill COVID-19 NT patients compared with healthy unexposed individuals. S-reactive frequencies were undetectable in critically ill COVID-19 patients [12] [13] [14] [15] .

A clinically usable test design is exemplified by assays to measure T-cell response to cytomegalovirus (CMV). These assays use unselected peptide mixtures representing the entire antigenic sequence of interest, a single activation marker, and no costimulators [18] [19] [20] . Here, we describe a minimal marker assay to characterize S-reactive T-and B-cells in healthy unexposed subjects and COVID-19 patients most of whom were hospitalized, with an emphasis on chronically immunosuppressed solid organ transplant recipients. A sizeable cohort of NT subjects is also included to enable robust conclusions and comparisons. Table S1 .

Stimulation of PBL from three healthy-NT with S peptides, cell permeabilization and ICS with specific fluorochrome-labeled detector antibodies showed that S-reactive T-cells which expressed CD154 also expressed IFN, a marker of cytotoxic T-cells (Figure 1a) . Further, CD154 was also co-expressed with IL-6 in B-cells (Figure 1b) . Thus, CD154 was used as a surrogate for S-reactive IFN+T-cells, and S-reactive IL-6+B-cells in all subsequent assays using nonpermeabilizing CD154 staining described previously 18, 21 .

Reproducibility: S-reactive CD154-expressing CD3, CD4, CD8 and CD19 cells were measured in duplicate assays performed on the same day, before and after 7 days of cryopreservation in liquid nitrogen, and before and after overnight storage or overnight shipment at ambient temperature. Mean coefficient of variation between duplicate assays was 2-10.6% in these various conditions (Tables S2-S5) . 

Twenty-four healthy and 29 COVID-19 patients were tested for circulating MDSCs. COVID-19 patients demonstrated higher frequencies of monocytic or M-MDSC (CD14 + HLA-DR -) compared with healthy subjects (Median ± SEM, 39 ± 7.8% vs 2.95 ± 1.1%, p= 9.8 E-08) (Figure 4c ). M-MDSC frequencies correlated negatively with S-reactive T-cell frequencies (Spearman's r = -0.276, p= 0.045 Figure 4d ). Polymorphonuclear or P-MDSC (CD15+CD14-CD11b+) frequencies were also higher in four COVID-19 subjects compared with 22 healthy subjects (median ± SEM, 64.2 ± 19.4% vs 1.25 ± 1.4%, p= 0.059, NS), and were negatively correlated with S-reactive Tcell frequencies (Spearman's r = -0.518, p= 0.007).

Our study found that S-reactive T-cells are present in pre-pandemic PBL samples from chronically immunosuppressed transplanted (Tr) recipients. This type of pre-existing T-cell immunity has been reported previously in the general population and is also seen in our study population of healthy NT subjects [12] [13] [14] [15] . Experimental evidence from previous studies implicates prior exposure to structurally similar human coronaviruses, which cause seasonal flu [16] [17] . We speculate that this explanation also applies to our Tr recipient cohort. Unlike some previous studies, however, we observed lower S-reactive T-cell frequencies in COVID-19 patients compared with healthy unexposed individuals. This decrease was significant and most Unlike previous studies, the majority of our COVID-19 patients, 91 of 103, were hospitalized, 58 without and 33 with severe disease requiring intubation for respiratory failure. This distribution represents a more severely affected infection cohort and may explain lower mean T-cell frequencies in infected patients compared with those who were healthy. Loss of T-cell immunity to the virus has been observed in critically ill patients in some previous studies 12 . Previous reports have also shown higher S-reactive T-cell frequencies in convalescent patients compared with unexposed subjects [12] [13] [14] [15] . These higher responses may be unique to the convalescent phase.

Another reason for the higher T-cell responses in COVID-19 infection in some previous studies may be the use of peptides with high affinity for selected HLA specificities, with or without adjunctive co-stimulators. This approach may have elicited larger T-cell responses from memory subsets. Our study patients were sampled at an average interval of 12 days after diagnosis of COVID-19 and assayed using unselected peptide stimulators, without adjunctive co-stimulators.

In previous studies, S-reactive T-cell frequencies averaging <1% have been observed in healthy unexposed subjects, compared with roughly 3% in our studies [12] [13] [14] [15] . Some of these studies counted S-reactive T-cells as those that co-expressed marker combinations like CD137 and CD69, but excluded S-reactive T-cells that expressed either marker alone 12, 13 . We have modeled our assay on clinical assays which measure antiviral T-cell immunity by employing a single marker. These assays use either IFN or CD154 as a marker of antigen-specific T-cells [18] [19] [20] 22, 23 . CD154 can substitute for IFN because it is co-expressed in viral antigen-specific T-cells 18, 24 . As a single marker of antigen-specific T-cells, CD154 can also be detected with non-permeabilizing methods.

Alloantigen-specific T-cytotoxic memory cells that express CD154 have met criteria for regulatory approval to predict transplant rejection 25 . S-reactive T-cell frequencies averaging 3% in our healthy unexposed subjects have also been observed among proliferating S-reactive T-cells in a previous study 14 . We cannot fully explain higher average frequencies in healthy unexposed Tr compared with NT subjects (mean 3.1 vs 4.2 %, p=0.042, Table S6 ). However, extended ex vivo exposure of normal human PBL to pro-apoptotic anti-lymphocyte antibodies enriches apoptosisresistant alloantigen-reactive CD154+T-cells among surviving PBL 26 Of great interest is the observation that Tr recipients also demonstrated a lower incidence of IgG antibodies to the RBD component of the S protein after COVID-19 infection compared with NT recipients, 2 of 7 vs 3 of 16, p=0.011. The incidence of anti-S IgG antibodies was similar between the T and NT groups. The RBD sequence is a component of the less conserved N-terminal S1 sequence of the SARS-CoV-2 spike protein. The S1 protein has 60% sequence similarity to hCoV.

As such, the RBD sequence may be less immunogenic when presented to the host immune system for the first time, compared with the more conserved C-terminal S2 sequence, which has 80% homology with hCoV. Test positivity was based on an OD 490 of 0.45 or greater in the ELISA antibody binding assay. The amount of IgG antibody reflected by OD 490 readings was also lower in Tr compared with NT patients for anti-spike IgG (p=0. 16 Figure S1 . Scatterplots acquired from assay reaction conditions for CD3, CD4, CD8 and CD19 cells are shown in Figure S2 .

Frequencies for each subset which were reactive to the S peptide mixture were analyzed further after subtracting corresponding background frequencies.

response to stimulation with the pp65-CMV antigen and PMA, respectively 18 .

Serological assay to detect SARS-CoV-2 antibody: 96-well microtiter plates were coated overnight at 4 0 C with commercially available S-protein (Cat # 46328, LakePharma, San Carlos, CA,) at 2 ug/ml, and blocked for 1hr with PBS-Tween + 3% milk powder (weight/volume).

Precoated wells were incubated with diluted samples for 2 hours, followed by anti-human IgG (Fab specific) HRP labeled secondary antibody 1:3000 in PBS-T containing 1% milk for 1 hour.

After adding substrate (OPD solution), followed by 50 μl of 3M hydrochloric acid to stop the reaction, plates were read at 490 nm on a spectrophotometer. With all samples, inactivated human AB serum was used as a negative control, while monoclonal antibody CR3022 was used as a positive control. Results were read on a plate reader as optical density at 490 nm. An optical density of 0.45 or greater was considered a positive test as reported earlier 33 . The negative control reaction shows autofluorescence in the absence of fluorochrome-labeled CD154 antibody. Figure S1. of table) and PMA stimulation (lower half of table). Variation is measured as the coefficient of variation (CV %). Variation is measured as the coefficient of variation (CV %). 

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Covid-19 and Kidney Transplantation

Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

History and recent advances in coronavirus discovery

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2

CD154-expressing CMV-specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation

A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point

Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children

Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection -United States

TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals

A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles

Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes

Severe COVID-19 is marked by a dysregulated myeloid cell compartment

Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)

Severe COVID-19 is marked by a dysregulated myeloid cell compartment

Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers

Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies

The Role of Myeloid-Derived Suppressor Cells in Viral Infection

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards